MarketCapExport financials
Health Catalyst (HCAT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Health Catalyst Financial Ratios 2025-2011 | HCAT
Brief overview of Health Catalyst's multiples and efficiency
The review covers five available annual periods spanning 2021 to 2025.
The latest available valuation ratios are P/S 0.4x (median 1.63x), P/B 0.51x (median 1.31x). Multiples are on average 68.3% below their own medians. Shares look cheaper than their recent historical valuation.
Current measures of operating quality are ROE -72.4%, ROA -35.4%, ROCE -65.4%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
On PEG (0.19x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The time from paying for inputs to receiving cash fell from 58.5 days to 44.4 days. Cash turnover improved.
Overall picture
Health Catalyst's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Health Catalyst
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.7 | -4.3 | -4.1 | -5.4 | -12.3 | -15.0 | -10.4 | - | - | - | - | - | - | - | - |
P/S |
0.4 | 1.0 | 1.6 | 2.7 | 7.8 | 9.1 | 4.0 | - | - | - | - | - | - | - | - |
EPS |
-2.5 | -1.1 | -2.1 | -2.6 | -3.2 | -2.9 | -12.9 | -23.8 | -12.1 | - | - | - | - | - | - |
EV (Enterprise Value) |
331 M | 542 M | 710 M | 956 M | 2 B | 1.93 B | 708 M | 457 M | 347 M | - | - | - | - | - | - |
EBITDA per Share |
-1.58 | -0.47 | -1.5 | -1.71 | -2.23 | -1.96 | -2.44 | - | - | - | - | - | - | - | - |
EV/EBITDA |
-3.0 | -19.1 | -8.4 | -10.4 | -18.6 | -26.7 | -14.3 | - | - | - | - | - | - | - | - |
PEG |
-0.02 | 0.19 | - | - | - | 0.22 | -0.02 | - | - | - | - | - | - | - | - |
P/B |
0.5 | 0.8 | 1.3 | 1.8 | 3.6 | 6.2 | 3.1 | - | - | - | - | - | - | - | - |
P/CF |
171.2 | 20.5 | -14.6 | -21.1 | -81.4 | -65.8 | -17.1 | - | - | - | - | - | - | - | - |
ROE % |
-72.41 | -19.03 | -32.20 | -32.33 | -29.35 | -41.66 | -29.95 | - | - | - | - | - | - | - | - |
ROA % |
-35.41 | -8.09 | -16.83 | -18.26 | -18.41 | -19.91 | -19.88 | - | - | - | - | - | - | - | - |
ROCE % |
-65.45 | -19.11 | -34.58 | -32.94 | -27.51 | -34.82 | -21.59 | - | - | - | - | - | - | - | - |
Current Ratio |
2.0 | 1.7 | 2.1 | 2.3 | 2.7 | 1.9 | 5.5 | - | - | - | - | - | - | - | - |
DSO |
68.2 | 69.9 | 66.8 | 63.9 | 73.2 | 73.3 | 64.9 | - | - | - | - | - | - | - | - |
DPO |
23.8 | 19.9 | 12.3 | 11.6 | 14.7 | 16.7 | 17.5 | - | - | - | - | - | - | - | - |
Operating Cycle |
68.2 | 69.9 | 66.8 | 63.9 | 73.2 | 73.3 | 64.9 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
44.4 | 50.0 | 54.5 | 52.3 | 58.5 | 56.7 | 47.4 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Health Catalyst
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.55 | -1.53 | -0.32 | -0.59 | -0.35 | - | -0.24 | -0.23 | -0.35 | -0.39 | -0.58 | -0.6 | - | -0.84 | - | -0.42 | - | -0.82 | -0.8 | -0.65 | - | -0.68 | -0.71 | -0.47 | - | -1.4 | -21.98 | -16.21 | - | -3.71 | -3.53 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.34 | -1.3 | -0.07 | -0.35 | -0.11 | - | -0.06 | -0.09 | -0.21 | -0.25 | -0.43 | -0.43 | - | -0.61 | - | -0.24 | - | -0.64 | -0.54 | -0.38 | - | -0.46 | -0.33 | -0.41 | - | -0.65 | -1.44 | -1.83 | - | -3.06 | -3.53 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-139.06 | -105.16 | -28.94 | -26.03 | -20.00 | -13.70 | -19.46 | -23.68 | -28.08 | -32.71 | -31.62 | -30.54 | -22.35 | -35.34 | -24.94 | -35.50 | -30.83 | -40.72 | -43.28 | -36.63 | -26.08 | -36.75 | -32.18 | -29.18 | -22.84 | -18.34 | -2.51 | -6.84 | - | 4.50 | 5.16 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-48.68 | -40.03 | -16.19 | -16.92 | -14.68 | -12.01 | -12.01 | -12.01 | -12.01 | -14.74 | -16.38 | -18.23 | -13.82 | -13.82 | -13.82 | -18.79 | -16.06 | -20.79 | -20.77 | -17.43 | -12.46 | -19.55 | -18.35 | -18.18 | -15.16 | -30.36 | -40.69 | -4.54 | - | -15.21 | -17.41 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-129.21 | -98.38 | -25.16 | -24.31 | -20.02 | -14.67 | -21.10 | -26.12 | -30.31 | -34.32 | -32.95 | -31.77 | -23.15 | -34.86 | -24.47 | -33.51 | -28.45 | -36.95 | -34.92 | -29.76 | -20.72 | -31.05 | -27.22 | -27.09 | -20.53 | -16.13 | -0.77 | -5.53 | - | 4.40 | 5.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.4 | 1.5 | 2.3 | 2.3 | 1.7 | 1.7 | - | - | - | 2.2 | 2.2 | 2.2 | 2.3 | - | - | 2.4 | 2.7 | 2.9 | 2.0 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 3.0 | 3.0 | 3.0 | 3.0 | 1.5 | 1.5 | 1.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
65.4 | 76.9 | 76.8 | 74.8 | 69.7 | - | - | - | 28.1 | 60.9 | 71.2 | 67.8 | - | - | - | 61.3 | - | 70.0 | 71.1 | 77.0 | - | 93.4 | 101.9 | 76.7 | - | 63.8 | 68.4 | 71.6 | - | 76.9 | 55.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
25.6 | 21.5 | 16.4 | 19.2 | 21.5 | - | - | - | 7.5 | 15.6 | 19.9 | 16.3 | - | - | - | 14.2 | - | 13.8 | 15.0 | 16.6 | - | 20.0 | 21.0 | 17.0 | - | 17.7 | 18.7 | 14.3 | - | 9.7 | 6.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 76.8 | 74.8 | 69.7 | - | - | - | - | 58.2 | - | - | - | - | - | 61.3 | - | 70.0 | 71.1 | 77.0 | - | 93.4 | 101.9 | 76.7 | - | 63.8 | 68.4 | 71.6 | - | 76.9 | 55.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 60.4 | 55.6 | 48.1 | - | - | - | - | 46.4 | - | - | - | - | - | 47.1 | - | 56.1 | 56.1 | 60.3 | - | 73.4 | 80.8 | 59.8 | - | 46.1 | 49.7 | 57.3 | - | 67.2 | 48.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Health Catalyst, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
GoodRx Holdings
GDRX
|
$ 3.53 | 4.13 % | $ 1.26 B |  USA |
 |
HealthEquity
HQY
|
$ 95.89 | 0.25 % | $ 8.26 B | USA |
 |
HealthStream
HSTM
|
$ 29.6 | 1.68 % | $ 889 M | USA |
 |
Omnicell
OMCL
|
$ 33.57 | 2.38 % | $ 1.54 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 7.72 | 5.9 % | $ 143 M | USA |
 |
Progyny
PGNY
|
$ 27.73 | 1.39 % | $ 2.36 B | USA |
 |
Phreesia
PHR
|
$ 10.34 | 0.29 % | $ 618 M | USA |
 |
Schrödinger
SDGR
|
$ 20.55 | 8.02 % | $ 1.51 B | USA |
 |
Teladoc Health
TDOC
|
$ 6.54 | 6.09 % | $ 1.15 B | USA |
 |
10x Genomics
TXG
|
$ 69.83 | 1.81 % | $ 8.71 B | USA |
 |
Veeva Systems
VEEV
|
$ 265.27 | 1.09 % | $ 43.4 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
American Well Corporation
AMWL
|
$ 13.92 | 6.58 % | $ 223 M | USA |
 |
Evolent Health
EVH
|
$ 4.06 | 0.48 % | $ 464 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.75 | 4.0 % | $ 2.56 M |  China |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
So-Young International
SY
|
$ 2.67 | 0.74 % | $ 208 M | China |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |